Retatrutide — a triple GIP/GLP-1/glucagon receptor agonist — research profile and the documentation US laboratories expect.
Retatrutide is a single-molecule triple agonist engaging the GIP, GLP-1, and glucagon receptors. Published Phase II data position retatrutide as one of the most metabolically active research peptides characterized to date in the Australia literature.
Mechanism
- GIP receptor agonism
- GLP-1 receptor agonism
- Glucagon receptor agonism (energy expenditure axis)
- Fatty-acid linker enabling weekly research dosing in published studies
Research use only. Pure Peptides supplies materials strictly for in vitro and laboratory research. Nothing in this article constitutes medical, therapeutic, or dosage advice for human or animal use.
